← Back to Screener
Bio-Rad Laboratories, Inc.Class A (BIO)
Price$303.34
Favorite Metrics
Price vs S&P 500 (26W)-7.01%
Price vs S&P 500 (4W)6.33%
Market Capitalization$8.19B
P/E Ratio (Annual)10.78x
All Metrics
P/CF (Annual)15.39x
Book Value / Share (Quarterly)$276.16
P/TBV (Annual)1.12x
Revenue Growth (3Y)-2.68%
Cash Flow / Share (Quarterly)$13.88
Price vs S&P 500 (YTD)-3.81%
Gross Margin (TTM)52.01%
Net Profit Margin (TTM)29.42%
EPS (TTM)$27.91
10-Day Avg Trading Volume0.24M
EPS Excl Extra (TTM)$27.91
Revenue Growth (5Y)0.29%
EPS (Annual)$27.85
ROI (Annual)8.78%
Gross Margin (Annual)52.01%
Net Profit Margin (5Y Avg)-10.04%
Cash / Share (Quarterly)$57.08
P/E Basic Excl Extra (TTM)10.78x
Revenue Growth QoQ (YoY)3.85%
EPS Growth (5Y)-26.09%
P/E Normalized (Annual)10.78x
ROA (Last FY)7.18%
Revenue Growth TTM (YoY)0.65%
EBITD / Share (TTM)$1.50
ROE (5Y Avg)-6.36%
Operating Margin (TTM)1.59%
Cash Flow / Share (Annual)$13.88
P/B Ratio1.10x
P/B Ratio (Quarterly)1.10x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.43x
Net Interest Coverage (TTM)0.10x
ROA (TTM)7.60%
EV / EBITDA (TTM)216.77x
EPS Incl Extra (Annual)$27.85
Current Ratio (Annual)5.62x
Quick Ratio (Quarterly)3.92x
3-Month Avg Trading Volume0.26M
52-Week Price Return27.36%
EV / Free Cash Flow (Annual)23.67x
P/E Incl Extra (TTM)10.78x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$269.70
P/S Ratio (Annual)3.17x
Asset Turnover (Annual)0.24x
52-Week High$343.12
Operating Margin (5Y Avg)11.71%
EPS Excl Extra (Annual)$27.85
CapEx CAGR (5Y)7.73%
Tangible BV CAGR (5Y)-5.54%
26-Week Price Return-0.12%
Quick Ratio (Annual)3.92x
13-Week Price Return-5.81%
Total Debt / Equity (Annual)0.16x
Current Ratio (Quarterly)5.62x
Enterprise Value$8,865.877
Revenue / Share Growth (5Y)2.35%
Asset Turnover (TTM)0.26x
Book Value / Share Growth (5Y)-3.46%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.65x
Pretax Margin (Annual)38.54%
Cash / Share (Annual)$57.08
3-Month Return Std Dev36.14%
Gross Margin (5Y Avg)54.44%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-37.40%
EBITDA Interim CAGR (5Y)-11.57%
ROE (Last FY)10.20%
Net Interest Coverage (Annual)0.08x
EPS Basic Excl Extra (Annual)$27.85
P/FCF (TTM)21.87x
Receivables Turnover (TTM)5.66x
EV / Free Cash Flow (TTM)23.67x
Total Debt / Equity (Quarterly)0.16x
EPS Incl Extra (TTM)$27.91
Receivables Turnover (Annual)5.66x
ROI (TTM)9.26%
P/S Ratio (TTM)3.17x
Pretax Margin (5Y Avg)-13.20%
Revenue / Share (Annual)$94.69
Tangible BV / Share (Annual)$269.70
Forward P/E29.48x
Free OCF CAGR (5Y)-4.69%
Price vs S&P 500 (52W)-7.28%
P/E Ratio (TTM)10.78x
Year-to-Date Return0.12%
5-Day Price Return3.80%
EPS Normalized (Annual)$27.85
ROA (5Y Avg)-4.13%
Net Profit Margin (Annual)29.42%
Month-to-Date Return8.82%
Cash Flow / Share (TTM)$-0.16
EBITD / Share (Annual)$1.50
Operating Margin (Annual)1.59%
LT Debt / Equity (Annual)0.16x
P/CF (TTM)15.39x
ROI (5Y Avg)-4.77%
P/E Excl Extra (TTM)10.78x
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$27.91
P/TBV (Quarterly)1.12x
P/B Ratio (Annual)1.10x
Inventory Turnover (TTM)1.65x
Pretax Margin (TTM)38.54%
Book Value / Share (Annual)$276.16
Price vs S&P 500 (13W)-8.19%
Net Margin Growth (5Y)-27.79%
Beta1.15x
P/FCF (Annual)21.87x
Revenue / Share (TTM)$95.61
ROE (TTM)10.86%
52-Week Low$211.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.80
3.80
3.80
3.80
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
TXG10x Genomics, Inc. Class A Common Stock | 5.18x | 16.56% | 69.13% | -9.49% | $24.59 |
About
Bio-Rad Laboratories manufactures diagnostic systems, quality controls, and life sciences instruments serving clinical labs, research institutions, and biopharmaceutical producers. The company derives 60% of revenue from clinical diagnostics and 40% from life sciences (including dPCR technology leadership), with balanced geographic exposure across Americas (40%), Europe (30%), and Asia (30%). A significant 33% ownership stake in Sartorius provides strategic exposure to the growing single-use biopharmaceutical manufacturing market.